Prometheus Biosciences Provides Corporate Updates at the 40th Annual J.P. Morgan Healthcare Conference

2 years ago

- Fast Track Designation granted from U.S. Food and Drug Administration for PRA023 for the treatment of Systemic Sclerosis-Associated Interstitial…

Closing of acquisition of SteelSeries

2 years ago

On October 6, 2021, GN announced an agreement to acquire SteelSeries - a global pioneer in premium software-enabled gaming gear.…

PDS Biotech Announces Presentation of PDS0101 Data at the 2022 Multidisciplinary Head and Neck Cancers Symposium

2 years ago

FLORHAM PARK, N.J., Jan. 12, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel…

LifeMD Expands Patient Offerings by Acquiring Leading Allergy Telehealth Platform

2 years ago

Acquisition of Cleared Further Diversifies LifeMD’s Telehealth Offerings to Encompass Allergy, Asthma, and Immunology Acquisition Expected to Synergize with LifeMD Virtual…

Levitee Labs Signs Retail Distribution Agreement with Body Energy Club for MONKE Nutraceuticals

2 years ago

In business for 20 years, Body Energy Club is the leading health supplement and vitamin retailer in Western Canada, with…

BrainsWay Announces Multiple Publications of New Real-World OCD Data for its Deep TMS™ System

2 years ago

Positive Data Support the Durability and Cost-Effectiveness of Deep TMS as a Treatment for Obsessive-Compulsive DisorderBURLINGTON, Mass. and JERUSALEM, Israel,…

gammaCore™ Non-Invasive Vagus Nerve Stimulation(nVNS) Receives Breakthrough Device Designation for Treatment of Posttraumatic Stress Disorder (PTSD)

2 years ago

nVNS reduces symptoms of PTSD by 31% in sham-controlled studyROCKAWAY, N.J., Jan. 12, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR),…

Xenon Pharmaceuticals Announces Collaboration with Neurocrine Biosciences Achieves $15.0 Million Regulatory Milestone

2 years ago

BURNABY, British Columbia, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that…

Longeveron Announces Publication of Lomecel-B Phase 2b Trial Design in Journal of Frailty and Aging

2 years ago

MIAMI, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or the "Company"), a clinical stage biotechnology company…

ImmixBio IMX-110 Produced 50% Positive Response Rate in First-Line-Therapy-Resistant Cancer, Surpassing the Standard of Care in Mice Study

2 years ago

IMX-110 Surpasses Standard of Care in Mice Cancer Study Immix Biopharma, Inc. (NASDAQ:IMMX) IMX-110 produced a 50% response rate after…